854 reports of this reaction
1.7% of all MYCOPHENOLIC ACID reports
#15 most reported adverse reaction
BLOOD CREATININE INCREASED is the #15 most commonly reported adverse reaction for MYCOPHENOLIC ACID, manufactured by Novartis Pharmaceuticals Corporation. There are 854 FDA adverse event reports linking MYCOPHENOLIC ACID to BLOOD CREATININE INCREASED. This represents approximately 1.7% of all 51,116 adverse event reports for this drug.
MYCOPHENOLIC ACID has an overall safety score of 88 out of 100. Patients taking MYCOPHENOLIC ACID who experience blood creatinine increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD CREATININE INCREASED is a less commonly reported adverse event for MYCOPHENOLIC ACID, but still significant enough to appear in the safety profile.
In addition to blood creatinine increased, the following adverse reactions have been reported for MYCOPHENOLIC ACID:
The following drugs have also been linked to blood creatinine increased in FDA adverse event reports:
BLOOD CREATININE INCREASED has been reported as an adverse event in 854 FDA reports for MYCOPHENOLIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD CREATININE INCREASED accounts for approximately 1.7% of all adverse event reports for MYCOPHENOLIC ACID, making it a notable side effect.
If you experience blood creatinine increased while taking MYCOPHENOLIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.